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Stage I Non-small Cell Lung Cancer: Results for Surgery in
a Patterns-of-Care Study in Sydney and for High-Dose
Concurrent End-Phase Boost Accelerated Radiotherapy
Peter H. Graham, MBBS, FRANZCR,* Shalini K. Vinod, FRANZCR,† and
Andrew C. Hui, FRANZCR‡
Purpose: To review results of resection or radical radiotherapy in
Sydney to inform patients contemplating treatment options for
early-stage non-small cell lung cancer (NSCLC).
Methods and Materials: Sixty-eight resected pathologic stage I
patients were identified from a patterns-of-care (POC) study of all
1993 and 1996 NSCLC patients treated at the South Western Sydney
Area Health Service and the Northern Sydney Area Health Service.
These were compared with 39 clinical stage I patients treated by
modern radiotherapy using an accelerated high-dose technique at St
George Hospital (SGH).
Results: Resected POC patients achieved a median survival rate of
67 months and a 5-year survival rate of 54% (95% CI, 40–66%).
SGH radiotherapy patients achieved a median survival rate of 43
months and a 5-year survival rate of 30% (95% CI, 13–48%). On
multivariate analysis, the only significant factor is performance
status, which may reflect comorbidity burden. Cancer-specific
5-year survival rates for surgery (59% [44–71%]) and for radiother-
apy (53% [28–72%]) are not significantly different.
Conclusions: Modern radiotherapy is a reasonable option for pa-
tients to consider for stage I NSCLC and is recommended for
medically inoperable patients rather than supportive care or obser-
vation.
Key Words: Surgery, Radiotherapy, Non–small-cell lung cancer.
(J Thorac Oncol. 2006;1: 796–801)
Surgery has been the standard treatment for stage I non-small cell lung cancer (NSCLC) patients since the 1960s.
Historically, results of radiotherapy have been poor, and this
treatment has been reserved for medically frail patients. This
has perpetuated the reputation of radiotherapy as essentially a
palliative treatment. The radiotherapy literature has been
criticized for the absence of a controlled study of radiother-
apy versus supportive care to prove a survival benefit.1 In
2003, authors were still claiming that surgery was the only
curative option.2 On this basis, patients may not be referred
for radiotherapy if medically unfit for surgery. In a patterns-
of-care (POC) study in Sydney, approximately half of stage I
patients not offered surgery received supportive care only.3
However, it is difficult to argue that a treatment with a proven
survival advantage from altered dose and fractionation will
not have a survival advantage compared with no immediate
radiation. The substantial comorbidity and staging biases that
impact negatively on radiotherapy results are well recog-
nized, but there are few opportunities to compare the results
of treatment in otherwise similar community-based patient
populations. In the late 1980s, Noordijk reported a compari-
son of 40 irradiated and 86 operated NSCLC patients aged
over 70.4 Overall 5-year survival rates were 15 and 26%, and
median survival rates were 27 and 23 months, respectively,
which were not statistically different. A POC study in the
South Western Sydney Area Health Service and the Northern
Sydney Area Health Service has provided a contemporary
surgical population representing a substantial proportion (es-
timated 42%) of operated patients in Sydney against which
our current radical radiotherapy results can be compared.3
This paper provides results of resection and modern radical
radiotherapy in Sydney for patients and physicians contem-
plating treatment options for early-stage NSCLC.
MATERIALS AND METHODS
Two data sets were used to generate this report. The
first data set comes from a POC study for the South Western
Sydney Area Health Service and the Northern Sydney Area
Health Service. All of the patients diagnosed with lung cancer
in 1993 and 1996 had their staging, treatment, and outcomes
reviewed. The subset of 93 stage I (T1-2N0M0) NSCLC
patients were identified for this study. The pathological stage
was the stage allocated to those patients treated surgically
because this was the stage recorded by the cancer registry.
The number of patients who were identified as clinical stage
I and treated by resection but found to have a higher patho-
logical stage is unknown. Surgery was used for definitive
treatment of 68 patients (with none receiving adjuvant radio-
therapy), curative intent radiotherapy was used for nine
patients, palliative radiotherapy was used for four patients,
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and supportive care was used for 12 patients. The supportive
care patients had a median survival rate of 14 months, with no
survivors beyond 26 months. Additional data available in-
cluded age, ECOG performance status, histology, gender,
tumor size, and cause of death.
The second data set comes from a radiation oncology
lung cancer database of the St George Hospital (SGH) Cancer
Care Centre, comprising 464 cases accrued between 1995 and
2002. This sample is estimated to comprise approximately
20% of lung cancer cases in the South Eastern Sydney Area
Health Service during this time period.5 This sample of
patients from the South Eastern Sydney Area Health Service
is subject to referral patterns and biases. Clinical stage I
patients referred to the department were generally those
considered medically inoperable or who had adverse postop-
erative pathology. Seventy-one clinical stage I NSCLC pa-
tients had definitive management undertaken at the time of
accrual (rather than accrued at the time of relapse). Twenty-
three were treated by surgical resection. Nine were treated
using a hypofractionated course of radiotherapy of 48 Gy in
12 fractions. Thirty-nine were treated with curative high-dose
radiotherapy of 65 Gy in 35 fractions using a concurrent
end-phase boost. This delivered 45 Gy in 25 fractions plus 20
Gy in 10 fractions concurrently during the last 2 weeks of the
5-week treatment period, with a 6-hour interfraction interval.
Three-dimensional computer planning with density-heteroge-
neity correction was used. The technique is reported in detail
elsewhere (P. Graham P et al., Australasian Radiology; in
press 2006). These 39 patients who were treated with curative
radiotherapy are being compared with the 68 POC study
patients who were treated surgically. All of the data fields
available in the POC study were available in the SGH
database.
All SGH patients had been assessed by either or both
respiratory physician and cardiothoracic surgeon. Of the 18
with a forced expiratory volume in 1 second (FEV1)1.3, 17
were deemed unfit on the basis of respiratory inadequacy for
surgery and one on the basis primarily of cardiovascular
disease. Of the 21 with a FEV1 1.3 (four) or not recorded
(17), two were declined because they were older than 80,
eight were declined on the basis of respiratory compromise,
five were declined on the basis of cardiovascular illness, one
patient declined surgery, and for two the reason was not
recorded. A further three were declined by the surgeon,
including two who had proceeded as far as thoracotomy but
not resection.
The POC and SGH surgical groups were not combined
because the SGH surgical patients were generally those
referred for consideration of adjuvant treatment based on
adverse pathological findings after resection and were thus a
potentially biased subset of resected South Eastern Sydney
Area Health Service patients. The POC and SGH curative
radiotherapy groups were not combined because of the het-
erogeneity of POC radiotherapy, which was nonetheless al-
ways of a lower biological dose in the POC patients. CT
scanning was routine, but mediastinoscopy was not per-
formed in the SGH radiotherapy patients. Positron emission
tomography (PET) was not used for staging of patients in
either data set.
For the purposes of attributing causes of death for
cancer-specific survival analysis, death certificates were ac-
cepted as the definitive determinations. In the POC study
(surgery group) of 29 deaths, six were certified as attributable to
causes other than cancer. Of these, one was known to have had
local relapse, and three had had metastatic relapses. None were
attributed to cancer without known relapses. In the radiotherapy
series of 22 deaths, two were attributed to cancer despite no
known relapses, 10 were attributed to cancer with known re-
lapses (nine metastatic), and 10 had no known relapses and were
not attributed to cancer.
Statistical Methods
Statistical analysis was undertaken using STATAv7
software. Tabular comparisons used Pearson’s chi square for
categorical variables, t test for comparison of means, and
rank-sum for comparison of medians for continuous vari-
ables. Kaplan-Meier survival curves were compared using the
log-rank test. Variables assessed for influence on survival
(overall and cancer specific) were age, sex, squamous histol-
ogy, Eastern Cooperative Oncology Group (ECOG) perfor-
mance status, T stage, tumor size in millimeters, and treat-
ment group (surgery versus radiotherapy). Variables with a p
value less than 0.25 on univariate analysis were subsequently
entered into multivariate modeling and processed backwards
with sequential models assessed by the likelihood ratio test.
Survival figures include numbers at risk during at each time
period.
RESULTS
The two treatment groups’ demographics are summa-
rized in Table 1. The SGH radical radiotherapy and POC
surgery populations had similar distributions of sex, T stage,
histology, ECOG performance status, and follow-up. The
radiotherapy group was significantly older.
Fewer than 10% of stage I patients in the POC study
were treated with curative intent using radiotherapy, reflect-
ing the standard recommendation of surgical resection in







Males (no. [%]) 24 (62) 42 (62) 0.98
Age (mean [range]) 72 (53–84) 66 (36–86) 0.0008
ECOG 1 (no. [%])a 5 (13) 7 (12) 0.56
T2 (no. [%]) 26 (67) 47 (69) 0.79
T size (mean [range], mm) 33 (20–70) 39 (7–110) 0.11
T size (median) 30 40 0.12
Squamous (no. [%]) 17 (43) 26 (38) 0.59
Follow-up for survivors
(mean [range], months)
40 (11–88) 44 (1–90) 0.56
POC, patterns of care; ECOG, Eastern Cooperative Oncology Group. a ECOG
performance status not known for 11 surgery patients.
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medically fit patients. Seventy-three percent of POC patients
underwent surgery and achieved a median survival rate of 67
months and a 5-year survival rate of 54% (95% CI, 40–66%).
The SGH radiotherapy patients achieved a median survival
rate of 43 months and a 5-year survival rate of 30% (95% CI,
13–48%; hazard ratio, 1.56; p  0.12) (Figure 1). These are
not statistically significantly different. For T1 tumors, there is
no apparent advantage for surgery for at least 3 years, which
suggests that comorbidity impacts long-term survival rather
than tumor outcomes (hazard ratio, 1.07; p  0.80) (Figure
2). Univariate analysis of prognostic factors is summarized in
Table 2. On multivariate analysis, the only significant prog-
nostic factor for overall survival is ECOG performance sta-
tus, which may reflect comorbidity burden (ECOG1 versus
ECOG 0–1, HR death 2.7 [95% CI, 1.3–5.7], p  0.008)
(Figure 3). The cancer-specific 5-year survival rate for sur-
gery is 59% (44–71%), and for radiotherapy it is 53%
(28–72%) (Figure 4). ECOG performance status remained
the only significant prognostic factor (p  0.03).
The operating surgeon was known for 61 of the 68 POC
patients. Three surgeons accounted for 30 operations and 14
surgeons for the remaining 31. Higher-volume versus lower-
volume surgeon survival was not significantly different (haz-
ard ratio of death, 1.5; p  0.29). Surgical morbidity is
unknown from the POC database, but no deaths occurred
within 30 days of surgery.
68 54 47 38 32 12 5 2















Clinical Stage 1 Radiotherapy vs Pathological Stage 1 Surgery
Overall Survival
FIGURE 1. Overall survival for clinical stage I radiotherapy
versus pathological stage I surgery.
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FIGURE 2. Overall survival for patients with T1 tumors
treated with radiotherapy versus surgery.
TABLE 2. Univariate Analysis of Survival
Hazard ratio 95% CI p value
Surgery versus radiotherapy 0.639 0.365–1.118 0.117
T1 versus T2 stage 0.979 0.540–1.775 0.945
T size (mm) 0.987 0.967–1.00 0.193
aECOG PS 1 versus 0–1 2.726 1.297–5.728 0.008
Age 1.019 0.991–1.047 0.185
Female versus male 0.996 0.559–1.775 0.989
Squamous versus other histology 1.297 0.744–2.262 0.359
aECOG PS, Eastern Cooperative Oncology Group performance status.
84 67 55 41 31 14 7 4
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FIGURE 3. Overall survival. ECOG performance status 0 to
1 versus 1.
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FIGURE 4. Cancer-specific survival for patients with clinical
stage I radiotherapy versus pathological stage I surgery.
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The only short-term radiotherapy toxicity was grade 2
pneumonitis in three patients (7.7 %), from which all fully
recovered, with none having longer-term reductions in exer-
cise tolerance attributable to shortness of breath compared
with pretreatment levels. In the absence of intrathoracic
recurrence, long-term exercise tolerance was unaffected in 35
(90%), unknown in two (5%), and reduced after 2 years in
one (2.6%). One further patient with a pretreatment FEV1 of
0.6 liters also developed cardiac failure 6 months after radio-
therapy and required home oxygen.
DISCUSSION
The current international system for staging lung cancer
is based on outcomes of a series of over 5000 patients.6 In the
subset of clinical stage I patients, 5-year survival rates for
T1N0 (1A) and T2N0 (1B) were 61 and 37%, respectively,
compared with 67 and 57%, respectively, by pathological
stage. Surgery has long been considered the standard therapy
for stage I NSCLC. The only randomized comparison of
surgery and radiotherapy was published in 1963 and no
longer provides relevant evidence for comparing these two
modalities as they are currently available for stage I NSCLC.7
The study predated CT scanning for staging, included at least
a third of patients with gross mediastinal disease on preop-
erative chest x-ray and a third of patients with small-cell
histology, predated modern perioperative care, and employed
a crude radiotherapy technique using a low dose of radiation.
Nonetheless, 4-year survival for the subset of 37 NSCLC
patients was 30% for surgery and 6% for radiotherapy (p 
0.05).
Subsequently, radiotherapy has been considered an in-
ferior palliative treatment and reserved for those unfit for
surgery or who decline surgery. In the intervening four
decades, the technical aspects of radiotherapy have been
revolutionized with megavoltage treatment, three-dimen-
sional CT planning, multileaf collimation, and multiple-beam
techniques. In addition, the benefit of alterations in fraction-
ation and dose escalation have been demonstrated in random-
ized trials.8–10 For limited-volume treatment, as in stage I
NSCLC, radiotherapy morbidity is minimal and treatment
mortality is rare.1 Five-year overall survival rates of 30 to
45% have been reported in a number of radiotherapy series
using widely available photon-beam technology.11–15 Reeval-
uation of the role of radiotherapy in view of these improve-
ments is required.
Some patients decline surgery primarily because of the
short-term treatment mortality risk. One study demonstrated
that patients are willing to trade off 10% or more long-term
survival if it avoids short-term mortality.16 Surgical mortality
is dependent upon a number of factors, including institutional
surgical throughput volume,17 extent of surgery, and preex-
isting comorbidity.18 Compared with institutions with fewer
than nine procedures annually, the highest-volume institu-
tions (46) had an odds ratio for mortality of 0.7 for
lobectomy and 0.62 for pneumonectomy.18 In a randomized
comparison of lobectomy versus lesser surgery, mortality was
2.5 versus 0.8%.19 All pulmonary complications are increased
in those patients with chronic obstructive pulmonary disease
compared with those without (53 versus 19%, p  0.001),
and 30-day operative mortality is increased to 14 versus 3%
(p  0.003).20 Although surgery is the standard treatment
because of consistently better long-term survival in the liter-
ature, some patients face a significantly higher risk of imme-
diate mortality or treatment morbidity using surgery com-
pared with radiotherapy. Furthermore, when significant
comorbidities are present, overall survival is also substan-
tially impaired. In stage IA patients with cardiovascular
comorbidities, Ambrogi et al.2 reported a 5-year survival rate
of 33.3 compared with 71.9% in those without cardiovascular
comorbidity. Median survival for resected patients with a
FEV1 70% was 27.3 months compared with 41.8 months if
the FEV1 was 70%.20 Halving of survival outcomes gen-
erally expected from surgery because patients have signifi-
cant cardiovascular or respiratory comorbidities results in
outcomes no better, and perhaps worse, than those of radio-
therapy.
The outcomes for surgically treated patients in Sydney
in the 1990s are demonstrated in this study. Overall survival
differences compared with radiotherapy are smaller than
historically expected, and there is no difference in cancer-
specific survival between surgery and radiotherapy.
There are several potential reasons for the smaller-than-
expected difference seen between surgery and radiotherapy.
One potential problem relates to selection biases. It may be
argued that the surgical results are an inferior example of
surgical outcomes. The 5-year 54% (95% CI, 40–66%)
survival rate is inferior to those reported by major tertiary
referral centers in the United States, such as those of Moun-
tain (69%) and Memorial Sloan-Kettering (82%).6,21 A recent
Japanese randomized trial of adjuvant chemotherapy reported
5-year survival rates of 90 and 74% for stages IA and IB in
the surgical control arm.22 However, those selected for this
study did substantially better than those in a contemporane-
ous large Japanese series of 7408 patients whose survival was
79 and 60% for stages IA and IB.23 A Cancer and Leukemia
Group B stage I adjuvant chemotherapy trial resulted in 59%
4-year survival in the surgery control arm.24 Calculated from
the reported death rate per person per year, a randomized trial
of two surgical techniques achieved a 5-year survival rate of
54 to 63%.20 Other nonrandomized modern surgical series
also report 5-year survival rates in the 51 to 63% range for
completely resected stage I NSCLC.25–28 Clearly, the POC
cohort is not a superselected cohort with outcomes well short
of the best reported in the literature; however, they are
certainly within the range of results reported within the last
10 years for stage I. One possible reason is that the number of
nodes sampled to determine pathological stage I is unknown,
and the more nodes that are included in the dissection for
node negative cases, the better the reported survival rate.28
Patients underwent surgery by a number of surgeons,
but there was no discernible difference in survival rates
between frequent versus less frequent operators. Not all
surgeons who operated on the POC patients practice primar-
ily in the two Sydney Area Health Services that were sur-
veyed. This means that the distinction between frequent and
less frequent operators may be spurious because some sur-
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geons may be frequent operators for patients living outside of
the regions served by the South Western Sydney Area Health
Service or the Northern Sydney Area Health Service, which
defined the sample for the POC study. Perhaps all that can be
inferred is that there were not substantial differences in
outcome for these patients irrespective of where in Sydney
their surgery occurred or who operated. Operative mortality
in this series was nil, presumably indicating appropriate
medical selection, good operative technique, and periopera-
tive care. Most importantly, patients being treated in Sydney
should be informed of these results as part of the consent
process, although results by clinical stage would be most
relevant.
An opposite selection bias may be operating in the
radiotherapy patients, who may have been superselected
among radiotherapy patients. However, the radical high-dose
patients were 39 of 48 stage I patients treated at SGH by
radiotherapy, which is clearly not a highly selected small
subset of the radiotherapy population, although some degree
of selection operated. The small group of nine patients who
were treated to the lower dose of 48 Gy in 12 fractions were
older (mean age 77) and had higher ECOG performance
status scores (56% ECOG 1). Nonetheless, the radical
high-dose patients were generally judged medically unfit for
surgery and did not comprise a better prognosis subgroup
compared with the patients treated by surgery. The recorded
major prognostic factors are very similar between the surgical
and radical radiotherapy groups except for the significantly
older age profile of the radiotherapy patients. Pulmonary
function was not available in the POC surgery patients, so
this parameter could not be compared. The SGH radiotherapy
series uses high-dose radiation in a relatively short treatment
time of 5 weeks, which doubled survival results of a previous
cohort also treated in the pre-PET era using lower doses and
longer treatment times.29,30 There is nothing about this tech-
nique that restricts its use to the SGH cancer-care center. If it
were applied at other Sydney radiotherapy centers, similar
outcomes might be expected. However, at the moment, pa-
tients being informed of the option of radiotherapy at other
centers would also need to be informed of the results from
using older radiotherapy techniques if these older techniques
continue to be employed.
An alternative radiotherapy technique with very prom-
ising results but that is not yet widely available in most
Australian radiotherapy centers is stereotactic lung radiother-
apy. Onishi and others have reported overall survivals highly
competitive with those reported for surgery.31–33
Obviously, this study is neither designed nor powered
to prove the equivalence of surgery and radiotherapy, but it
does challenge the assumption that they differ by as much as
has been suggested by nonrandomized literature. In addition,
it should be remembered that overall survival comparisons in
this paper are still limited by the 5 to 20% absolute survival
advantage expected to be seen in surgically treated patients if
reporting is based on pathological stage rather than clinical
stage.6 Of course, if one were to design an ethically accept-
able randomized comparison, the study would have to be
powered to demonstrate equivalence with smaller differences
in survival than suggested here, which would require sub-
stantially greater numbers. Such a study also would need to
encompass early stopping rules because of the possibility of
survivals statistically diverging beyond clinically acceptable
limits. Should a randomized comparison of local treatment
modalities be considered?
A current Cochrane analysis determined that conclu-
sions about the efficacy of surgery for local NSCLC are
limited by the small number of participants studied and
methodological weaknesses of trials.34 Over the decades, a
number of authors have issued calls for randomized trials of
surgery versus conservative management.35–38 That such
studies have not occurred reflects both the general acceptance
of surgery as an effective, safe, and well-tolerated interven-
tion and the lack of acceptable alternative management op-
tions, whether supportive or active in nature. If one accepts
the possibility that radiotherapy may offer similar survival if
selection factors and additional treatments such as chemo-
therapy are equally applied, then additional issues would be
relative logistics and treatment morbidities.
For stage I NSCLC, radiotherapy mortality is rare, and
morbidity is generally minimal, with complications more
severe than grade 2 occurring in up to 3% of patients, and
usually only those with mediastinal radiotherapy.39 In our
series, grade 2 complications occurred in 7.7%. However,
none experienced greater than grade 2 short-term toxicity,
and long-term functional outcomes were excellent despite the
high rate of substantial baseline respiratory functional impair-
ment. Surgical mortality has already been discussed. Al-
though surgical morbidity is generally considered short term,
long-term postthoracotomy pain occurs in approximately
50% of patients and is severe and disabling in 5%, with no
significant differences attached to different surgical tech-
niques.40 Average hospital length of stay is 5 to 8 days, but
transfer to other care facilities or home nursing care is
required in 20 to 65% of cases, depending on whether the
procedure is video-assisted thoracic surgery or open thora-
cotomy.29,41 Average hospital stay in Japan, which includes
rehabilitation time to independent care at time of discharge, is
22 days.42 Average time until return to preoperative activity
levels is more than 6 months.43
In addition to the above considerations, PET scanning
now offers the opportunity for timely diagnosis of persistent
isolated local activity after radiotherapy, which could enable
salvage local treatment.43,44 With the safety net of a salvage
therapy option, perhaps the time is approaching to consider
offering patients a properly conducted randomized trial of
surgery versus modern radiotherapy as the local modality for
early-stage NSCLC.
Surgery remains the standard treatment to offer fit
patients with NSCLC; however, radiotherapy should be
strongly recommended if a patient is medically unfit for
resection. If radiotherapy is used and the intent is curative,
biologically high-dose accelerated radiotherapy should be
employed. For the moment, comparisons from an appropriate
randomized trial are not available. Nonetheless, for proper
informed consent, all patients should be aware of all the
treatment options ranging from supportive care to surgery,
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and where possible, results specific for their treating health
service and clinical stage should be provided.45,46 This study
provides such information for patients in Sydney.
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